Cipla Share Price Today | Stock Price & Cipla Share Screener

CIPLA Pharmaceuticals
Live Share Price NSE
₹1324.10
▼ -1.00 (-0.08%)
2026-10-19 00:00:00
Live Share Price BSE
₹1331.00
▲ 6.00 (0.45%)
2026-10-19 00:00:00

As of October 19, 2026, the live Cipla share price (NSE: CIPLA) is ₹1,324.10 on NSE and ₹1,331.00 on BSE, down 0.08% from the previous close, with shares trading between ₹1,321.60 and ₹1,339.00 in today's trading session, and a 52-week range of ₹1,192.40–₹1,645.10. Check CIPLA 52-week high low for the annual price range and momentum. Use the Cipla stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Cipla opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹6,612 and net income of ₹543, with EBITDA of ₹1,026, an operating margin of 14.0% and a profit margin of 8.2%.

Cipla Market Cap ₹107,049.32 Cr.
CIPLA P/E Ratio (TTM) 32.11
Cipla P/B Ratio 3.13
EPS (TTM) ₹48.03
Dividend Yield 0.97%
Debt to Equity 0.02
CIPLA 52 Week High ₹1645.10
Cipla 52 Week Low ₹1192.40
Operating Margin 14.00%
Profit Margin 8.21%
CIPLA Revenue (TTM) ₹6,612.00
EBITDA ₹1,026.00
Net Income ₹543.00
Total Assets ₹42,496.00
Total Equity ₹34,520.00

Cipla Share Price Chart

Track the current stock price of Cipla with an interactive chart. Analyse CIPLA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Cipla stock quote in one place.

The quote of ₹1,324.10 sits between the 52-week low of ₹1,192.40 and the 52-week high of ₹1,645.10, and the latest session moved -0.08% from the previous close.

Cipla Company Profile - Fundamental Screener

Screen Cipla company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CIPLA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Y K Hamied listed as chairperson or CEO, and it trades under ISIN INE059A01026.

Business Overview

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

Chairperson/CEO Y K Hamied
ISIN INE059A01026

Cipla Balance Sheet Screener

Screen CIPLA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹42,496, up from ₹37,387 in 2025.

Latest statistics put total assets at ₹42,496 and shareholder funds at ₹34,520, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 42,496 37,387 32,718 29,463 27,101 25,152 23,663 23,963 22,861 21,037
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 12,434 10,006 9,607 9,161 9,683 9,516 9,683 9,608 9,950 9,492

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 962 614 670 640 1,071 1,975 3,212 4,848 4,447 4,682
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 34,520 31,289 26,802 23,714 21,117 18,586 16,057 15,344 14,582 12,982
Share Capital 162 162 162 161 161 161 161 161 161 161
Reserves & Surplus 34,270 31,032 26,545 23,246 20,680 18,165 15,602 14,851 14,068 12,383

Cipla Income Statement Screener - Profit & Revenue Analysis

Screen Cipla income statement and profit fundamentals. Analyze CIPLA quarterly results. Cipla reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹6,612 and net profit was ₹543, equal to earnings per unit of ₹6.87, at an operating margin of 14%.

In that period expenses were ₹5,586, interest cost ₹13 and tax ₹165. The next period listed, 2026-Jun, shows revenue of ₹7,288 and net profit of ₹786.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 6,612 7,288 6,887 7,096 7,716 7,169 6,332 6,785 7,152 7,183 5,801 6,406 6,766 6,690 5,288
Expenses 5,586 5,927 5,192 5,179 5,695 6,095 4,847 4,978 5,165 5,084 4,748 4,835 4,944 5,051 4,568

Operating Costs and Margins

EBITDA 1,026 1,361 1,695 1,916 2,022 1,074 1,484 1,807 1,986 2,099 1,053 1,571 1,821 1,639 720
Operating Profit % 14.00% 16.00% 21.00% 24.00% 24.00% 12.00% 20.00% 25.00% 26.00% 27.00% 16.00% 23.00% 25.00% 22.00% 13.00%
Depreciation 383 304 309 253 297 278 288 247 272 280 346 239 290 233 290
Interest 13 17 14 14 13 14 18 18 15 15 34 16 26 30 18

Profit and Earnings

Profit Before Tax 707 1,082 1,504 1,770 1,854 893 1,259 1,611 1,789 1,916 745 1,375 1,594 1,474 448
Tax 165 296 290 478 500 219 327 436 484 342 224 377 439 405 77
Net Profit 543 786 1,214 1,292 1,353 674 932 1,176 1,305 1,575 522 998 1,155 1,068 371
EPS 6.87 9.77 15.13 16.07 16.73 8.37 11.63 14.58 16.13 19.45 6.51 12.34 14.01 13.08 4.49

Cipla Cash Flow Screener - Liquidity Fundamentals

Screen CIPLA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹3,940, and net cash flow was an inflow of ₹473.

Over the same period, investing activities used ₹2,234 and financing activities used ₹1,234.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 3,940 5,005 4,134 3,238 3,326 3,755 3,068 1,691 1,463 2,382
Investing Activities -2,234 -3,682 -2,983 -2,376 -1,858 -2,374 114 -1,688 -834 -1,304

Financing and Net Cash

Financing Activities -1,234 -1,293 -1,200 -958 -1,600 -1,240 -2,949 -349 -386 -1,326
Net Cash Flow 473 30 -49 -97 -132 141 234 -345 243 -248

Cipla Shareholding Pattern Screener

See Cipla shareholding pattern with promoter, FII, and DII holdings. Check Cipla promoter holding and ownership changes for CIPLA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 29.21%, foreign institutions 22.56%, domestic institutions 31.97% and the public 13.98%, spread across 584,217 shareholders.

The shareholder count was 584,217 in 2026-Mar, compared with 578,679 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 29.21% 29.21% 29.20% 29.19% 29.21% 29.21% 33.47% 30.91%

Institutional Investors

FII Holding 22.56% 20.21% 26.28% 25.25% 24.55% 23.93% 25.83% 27.81%
DII Holding 31.97% 34.63% 28.15% 29.26% 30.25% 30.72% 24.42% 24.95%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 13.98% 13.74% 14.13% 14.10% 13.82% 13.84% 14.20% 14.24%
Other Holding 2.28% 2.20% 2.23% 2.20% 2.16% 2.29% 2.08% 2.09%
Shareholder Count 584,217 578,679 543,420 549,655 534,587 540,521 436,154 463,569

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Cipla. Cipla dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹13.00 per unit for 2026-March, a yield of 0.98%, compared with ₹16.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹13.00, ₹16.00 and ₹13.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹13.00 0.98%
2025-March ₹16.00 1.31%
2024-March ₹13.00 0.90%
2023-March ₹8.50 0.57%
2022-March ₹5.00 0.56%
2021-March ₹5.00 0.49%
2020-March ₹4.00 0.49%
2019-March ₹3.00 0.71%
2018-March ₹3.00 0.57%
2017-March ₹2.00 0.37%

Cipla Stock Index Membership - Nifty & Sensex

See which indices include Cipla stock. Check CIPLA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 45 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE100.

Complete Index List

BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE100
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEDSI
BSE INDEX DOL100
BSE INDEX ESG100
BSE INDEX LCTMCI
BSE INDEX LMI250
BSE INDEX LRGCAP
BSE INDEX MFG
BSE INDEX SNSX50
BSE SENSEX SIXTY
BSE SENSEX SIXTY 65:35
GIFT NIFTY
INDIA VIX
NIFTY 100
NIFTY 200
NIFTY 50
NIFTY 500
NIFTY ALPHA QUALITY VALUE LOW VOLATILITY 30
NIFTY GROWSECT 15
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY QUALITY LOW VOLATILITY 30
NIFTY SHARIAH 25
NIFTY TOTAL MKT
NIFTY100 ENHANCED ESG
NIFTY100 EQL WGT
NIFTY100 ESG
NIFTY100 LOWVOL30
NIFTY50 EQL WGT
NIFTY50 SHARIAH
NIFTY50 VALUE 20
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
SENSEX NEXT 30

Cipla Market Events Screener - Corporate Actions

Get Cipla corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Cipla stock events that may affect CIPLA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 27, 2026, with a record date of October 27, 2026.

It is followed by Quarterly Result Announcement dated July 23, 2026 and Annual General Meeting dated June 25, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-27 2026-10-27 Quarterly Result Announcement NA -5.17%
2026-07-23 2026-07-23 Quarterly Result Announcement NA -1.26%
2026-06-25 2026-06-25 Annual General Meeting NA 11.27%
2026-06-05 2026-06-05 Dividend ₹ 13.00 /share 8.23%
2026-05-13 2026-05-13 Quarterly Result Announcement NA 5.66%
2026-01-23 2026-01-23 Quarterly Result Announcement NA -9.40%
2025-10-30 2025-10-30 Quarterly Result Announcement NA 3.54%
2025-07-25 2025-07-25 Quarterly Result Announcement NA -1.20%
2025-07-16 2025-07-16 Annual General Meeting NA -1.37%
2025-06-27 2025-06-27 Dividend ₹ 13.00 /share 0.08%
2025-06-27 2025-06-27 Dividend ₹ 3.00 /share 0.08%
2025-05-13 2025-05-13 Quarterly Result Announcement NA 6.81%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -7.57%
2024-10-29 2024-10-29 Quarterly Result Announcement NA -9.10%
2024-08-20 2024-08-20 Annual General Meeting NA 15.95%

Cipla Competitors Screener - Peer Stocks Comparison

Screen CIPLA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 421,995 34.86 61,674 12.69% 11,565 37.01
Divis Laboratories 242,758 82.05 11,067 13.95% 2,568 46.92
Torrent Pharmaceuticals 173,406 81.26 13,886 20.34% 2,138 32.77
Zydus Life Science 112,020 24.78 27,658 17.64% 5,026 44.73
Laurus Labs 111,310 100.10 6,868 22.01% 890 60.45
Cipla 107,049 32.11 29,045 2.24% 3,870 40.32
Dr Reddys Laboratories 102,916 32.01 35,059 3.90% 4,158 57.84
Aurobindo Pharma 95,910 25.97 34,145 5.56% 3,503 47.98
Mankind Pharma 93,988 47.04 14,636 14.85% 1,938 37.77
Lupin 89,702 16.14 29,039 26.75% 5,356 35.35

Cipla Company Announcements - News & Reports Screener

Screen CIPLA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 19, 2026.

The next most recent announcements are dated October 17, 2026 and September 28, 2026.

Date Update Actions
2026-10-19 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-28 Board Meeting Intimation for The Quarter And Half Year Ended 30Th September 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-09-24 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-09-22 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-18 Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-09-03 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-03 Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company -
2026-09-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-31 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-08-28 Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip Long Island NY USA -
2026-08-27 Announcement under Regulation 30 (LODR)-Restructuring -
2026-08-27 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-26 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-08-25 USFDA Inspection At CompanyS Manufacturing Facility In Pithampur India -
2026-08-19 Announcement under Regulation 30 (LODR)-Scheme of Arrangement -
2026-08-11 Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-08-04 Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USA -
2026-07-31 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-07-27 Cipla Receives U.S. FDA Approval For Generic Advair Diskus® -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,324.10, within a 52-week range of ₹1,192.40 to ₹1,645.10. The P/E ratio is 32.11 and the P/B ratio is 3.13, with earnings per unit of ₹48.03. Market capitalisation stands at ₹107,049.32 Cr and the dividend yield is 0.97%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 21, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.